PFE Stock Analysis: Pfizer | NYSE
Drug Manufacturers - General | NYSE, USA | Market Cap: 175.499m USD | 12M Return: 28.4% | US7170811035 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 932M
EPS Trend: 73.4%
Qual. Beats: 1
Rev. Trend: 77.4%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pfizer Inc. is a U.S.-headquartered biopharmaceutical company that discovers, develops, manufactures, and sells medicines globally across three operating segments: Biopharma, PC1, and Pfizer Ignite. Founded in 1849 and listed on the NYSE since 1942, the company generates revenue from a broadly diversified portfolio spanning internal medicine, vaccines, inflammation and immunology, rare diseases, oncology, biosimilars, and sterile injectables, anchored by blockbuster franchises such as Eliquis, the Prevnar vaccine family, Paxlovid, the Vyndaqel family, Ibrance, and Xtandi.
The business model reflects the typical large-cap pharmaceutical approach of deriving the majority of revenue from a concentrated set of patent-protected blockbusters while supplementing growth through collaborations and licensing deals, notably with Bristol-Myers Squibb (Eliquis), Astellas (Xtandi), Merck KGaA, and BioNTech. Like peers in the GICS Pharmaceuticals sub-industry, Pfizer faces ongoing pressure from patent expirations and biosimilar competition, which it offsets through heavy R&D investment, lifecycle management of existing assets, and bolt-on acquisitions in growth areas such as oncology ADCs and rare diseases.
- COVID product revenue decline pressures total sales growth
- Eliquis patent cliff threatens top-line revenue base
- Seagen acquisition expands oncology pipeline and revenue base
| Net Income: 4.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.79 > 1.0 |
| NWC/Revenue: 20.88% < 20% (prev 16.45%; Δ 4.43% < -1%) |
| CFO/TA 0.07 > 3% & CFO 14.2b > Net Income 4.03b |
| Net Debt (48.4b) to EBITDA (13.5b): 3.59 < 3 |
| Current Ratio: 1.42 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.75b) vs 12m ago 0.65% < -2% |
| Gross Margin: 73.37% > 18% (prev 73.40%; Δ -0.02% > 0.5%) |
| Asset Turnover: 30.79% > 50% (prev 30.08%; Δ 0.71% > 0%) |
| Interest Coverage Ratio: 2.57 > 6 (EBIT TTM 6.97b / Interest Expense TTM 2.71b) |
| A: 0.06 (Total Current Assets 45.0b - Total Current Liabilities 31.7b) / Total Assets 205b |
| B: 0.56 (Retained Earnings 115b / Total Assets 205b) |
| C: 0.03 (EBIT TTM 6.97b / Avg Total Assets 207b) |
| D: 0.77 (Book Value of Equity 89.0b / Total Liabilities 115b) |
| Altman-Z'' = 3.30 = A |
| DSRI: 0.77 (Receivables 14.2b/18.1b, Revenue 63.6b/62.8b) |
| GMI: 1.00 (GM 73.40% / 73.37%) |
| AQI: 1.00 (AQ_t 0.69 / AQ_t-1 0.68) |
| SGI: 1.01 (Revenue 63.6b / 62.8b) |
| TATA: -0.05 (NI 4.03b - CFO 14.2b) / TA 205b) |
| Beneish M = -3.21 (Cap -4..+1) = AA |
As of November 07, 2026, the stock is trading at USD 29.39 with a total of 48,232,765 shares traded. Over the past week, the price has changed by -2.30%, over one month by +8.43%, over three months by +13.81% and over the past year by +28.41%.
Current recommended Stop Loss: 28.00 (which is 4.7% or 1.9 ATR below the current price).
Pfizer has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold PFE.
- StrongBuy: 8
- Buy: 1
- Hold: 17
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 29.5 | 0.2% |
P/E Trailing = 43.9857
P/E Forward = 10.3093
P/S = 2.7583
P/B = 2.0072
P/EG = 13.7457
Revenue TTM = 63.6b USD
EBIT TTM = 6.97b USD
EBITDA TTM = 13.5b USD
Long Term Debt = 60.8b USD (from longTermDebt, last fiscal year)
Short Term Debt = 2.67b USD (from shortTermDebt, last quarter)
Debt = 62.7b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 48.4b USD (calculated: Debt 62.7b - CCE 14.3b)
Enterprise Value = 224b USD (175b + Debt 62.7b - CCE 14.3b)
Interest Coverage Ratio = 2.57 (Ebit TTM 6.97b / Interest Expense TTM 2.71b)
EV/FCF = 19.00x (Enterprise Value 224b / FCF TTM 11.8b)
FCF Yield = 5.26% (FCF TTM 11.8b / Enterprise Value 224b)
FCF Margin = 18.53% (FCF TTM 11.8b / Revenue TTM 63.6b)
Net Margin = 6.34% (Net Income TTM 4.03b / Revenue TTM 63.6b)
Gross Margin = 73.37% ((Revenue TTM 63.6b - Cost of Revenue TTM 16.9b) / Revenue TTM)
Gross Margin QoQ = 75.71% (prev 72.78%)
Tobins Q-Ratio = 1.09 (Enterprise Value 224b / Total Assets 205b)
Interest Expense / Debt = 4.32% (Interest Expense 2.71b / Debt 62.7b)
Taxrate = 4.37% (186.0m / 4.26b)
NOPAT = 6.66b (EBIT 6.97b * (1 - 4.37%))
Current Ratio = 1.42 (Total Current Assets 45.0b / Total Current Liabilities 31.7b)
Debt / Equity = 0.70 (Debt 62.7b / totalStockholderEquity, last quarter 89.0b)
Debt / EBITDA = 3.59 (Net Debt 48.4b / EBITDA 13.5b)
Debt / FCF = 4.11 (Net Debt 48.4b / FCF TTM 11.8b)
Total Stockholder Equity = 87.7b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.95% (Net Income 4.03b / Total Assets 205b)
RoE = 4.60% (Net Income TTM 4.03b / Total Stockholder Equity 87.7b)
RoCE = 4.69% (EBIT 6.97b / Capital Employed (Equity 87.7b + L.T.Debt 60.8b))
RoIC = 3.87% (NOPAT 6.66b / Invested Capital 172b)
WACC = 6.19% (E(175b)/V(238b) * Re(6.93%) + D(62.7b)/V(238b) * Rd(4.32%) * (1-Tc(0.04)))
Discount Rate = 6.93% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 52.13 | Cagr: 0.43%
[DCF] Terminal Value 77.75% ; FCFF base≈11.2b ; Y1≈12.7b ; Y5≈18.1b
[DCF] Fair Price = 39.55 (EV 274b - Net Debt 48.4b = Equity 225b / Shares 5.70b; r=8.35% [WACC [floored]]; 5y FCF grow 13.60% → 2.50% )
EPS Correlation: 73.39 | EPS CAGR: 31.34% | SUE: 1.15 | # QB: 1
Revenue Correlation: 77.36 | Revenue CAGR: 4.51% | SUE: 0.77 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.68 | Chg30d=+1.31% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=3.01 | Chg30d=+1.12% | Revisions=-50% | GrowthEPS=-6.5% | GrowthRev=+0.2%
EPS next Year (2027-12-31): EPS=2.91 | Chg30d=+0.42% | Revisions=-18% | GrowthEPS=-3.4% | GrowthRev=-4.5%
[Analyst] Revisions Ratio: -38% (up=6, down=15)